Jaypirca Combination Therapy Improves Outcomes for CLL/SLL Patients

Eli Lilly announced positive Phase 3 trial results for Jaypirca (pirtobrutinib) in combination with other drugs. The treatment significantly reduced the risk of disease progression or death by 45% in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma. This represents a notable advancement for individuals battling these conditions.